Ēnel Health

The truth engine for the consumer wellness economy.

Real-world evidence for what people take, try and do. Scroll for our mission and our why, then pick one of three routes.

Scroll to begin.

Our mission

We measure what happens in people every day, and check it against the evidence.

Each day, members tell us in under two minutes what they took and how they felt, by text, voice or video. Our models turn every answer into data.

A spoken check-in

“I took 250 mcg of BPC-157 this morning, and my shoulder felt looser by lunch.”

The data our models take from it

WhatBPC-157
How much250 mcg
WhenMorning
How it feltShoulder looser

Illustration, not member data.

Our vision

Every claim about what people take should be testable in daily life.

Each claim opens a study, and each study closes with the claim accepted or declined, in any country that approves it.

  • A member brings a claim, or it comes from the published science.

    New
  • Members check in every day, and their answers fill the study.

    Studying
  • The team decides from the evidence, and the claim is locked.

    Accepted or Declined

Claim status in the Ēnel Health app, as of 15 November 2026.

Live in the USOther countries next

Our why

Three reasons we built Ēnel.

What no single source can see, what the wellness market runs on, and what peptide science is missing.

1The full picture

Each source sees one part of a person's health.

2The market

A $2 trillion economy that runs mostly on claims.

3The science

Peptides are measured at the bench, rarely in people.

The full pictureThe marketThe science

Each source sees one part of a person's health. Ēnel adds them up.

A clinic sees a visit, a wearable sees a signal, a forum holds unchecked reports, and members tell us their day.

Wellness is a $2 trillion economy that runs mostly on claims.

Evidence from people is worth a great deal, and wellness evidence has to come from daily life, because health records do not see it.

Science can measure a peptide at the bench, but rarely in people.

Of 36 published studies of BPC-157, one was in people.

Clinic2 visits
+Wearableno context
+Forumsunchecked
+Check-insin their words
=Ēnelevery day

One person's 28 days, as an illustration. Ēnel read 73,129 posts from 8,954 authors on peptide and GLP-1 forums.

$2T

The wellness economy.

$1.9B

Roche bought Flatiron Health for its oncology evidence in 2018.

$6B+

Tempus AI listed in 2024, valued on its data and AI.

the lack of any human data

FDA reviewers, July 2026, on a peptide they recommended against.

Clinic visitWearableForum reportDaily check-in
35 in cells or animals1 in people

Ēnel Health forum analysis, 2011 to 2026, as of 13 November 2026.

McKinsey & Company, 2025. Roche, 15 February 2018. Axios and Reuters, June 2024.

Vasireddi et al., HSS Journal, 2025. FDA briefing documents for the Pharmacy Compounding Advisory Committee, July 2026.

What Ēnel measures

What we measure in people, and what it shows.

The data we hold for each person, how a short check-in becomes data, and the patterns it shows over time.

1The data

Four layers for the same person, side by side.

2The check-ins

How a short check-in becomes data.

3The patterns

What changes over months, in one person and in many.

The dataThe check-insThe patterns

Our value is all of the data together, and the patterns it shows over time.

We hold four layers for the same person, side by side.

Our models turn a short check-in into structured data.

They read words, photos and routines the same way for everyone, so a month in Ohio compares with a month in California.

Inside a spoken or filmed check-in, our models measure the voice and the face.

We study these signals beside what the member reports that day, and the methods stay ours.

Members' data shows patterns over months, in one person and across many.

For one person it shows what changes after they start, stop or switch, and across people it shows who responds.

  1. Daily check-insUnder 2 minutes a dayLive
  2. MeasuresWearables, the phone and typingLive
  3. CommunityForums and word of mouth, checkedLive
  4. Ēnsights1,771 graded entriesLive

Daily check-ins

  1. 1

    Words, voice and videoBecome data on what, how much and how it felt.

  2. 2

    Label photosThe label is read and matched to a verified product.

  3. 3

    Each scheduleOur models learn when a person doses and ask on those days.

Voice

A voice changes with emotion, anxiety, mood and illness.

  • Pitch
  • Jitter and shimmer
  • Harmonics to noise
  • Cepstral peak (CPPS)
  • Speaking and pause time
  • +

Face

It runs only for members who say yes to video.

  • Heart rate from the skin
  • Blinks per minute
  • Expression units, such as a smile
  • Eye and head movement
  • +

A recording too noisy to measure is held back with its reason, and the research view shows totals across members, never one person.

DHTs allow for data collection in real-time and in real-world settings, which can provide a more comprehensive picture of a participant's health status than historical data only captured during periodic trial visits

Beth Kunkoski, FDA Office of Medical Policy. Voice and video run with the member's AI permission.

Illustration over twelve weeks, not member data. Each pattern is also compared with the published science.

One person's sleep scoreCohort, middle and rangeStarted a product, week 4

Ēnsights, the Ēnel Health wiki, count of entries on 16 November 2026.

FDA, Guidance Recap Podcast on digital health technologies for remote data acquisition.

Fagherazzi et al., Digital Biomarkers, 2021. Rodrigo and Duñabeitia, Brain Sciences, 2025. Voice is measured with Praat, the standard tool of speech science.

Pick your route Partnership to build

A lab, a pharmacy and a research group each bring what the other two lack.

Each partner is a route. Click one to open it.Tap one to open it.

Members check in every day.

Manufacturing and commercial productsPharmacies and product developers

Bring products made under the HHS conditions or for sale, each with its lot and product claims.

Open this route

Manufacturing and commercial products to scienceLot data tells a lab whether a weak response came from the person or from the vial.

ScienceLabs and pharma teams

Bring the question, the molecule and the lab work.

Open this route

Science to researchAn effect seen in people sends a lab back to the bench, and gives the next study a measure to add.

Academics and researchAcademic groups

Bring study design, ethics review and analysis.

Open this route

Research to manufacturing and commercial productsOne protocol and one consent follow each partner's patients and customers the same way in every state.

  1. Manufacturing and commercial productsPharmacies and product developersOpen
  2. Lot data tells a lab whether a weak response came from the person or from the vial.
  3. ScienceLabs and pharma teamsOpen
  4. An effect seen in people sends a lab back to the bench, and gives the next study a measure to add.
  5. Academics and researchAcademic groupsOpen
  6. One protocol and one consent follow each partner's patients and customers the same way in every state, back to manufacturing and commercial products.

Route 1 of 3, science

Ēnel gives peptide science a daily human readout, from new uses to new products.

This route is for scientists who work on peptides, proteins and sensors, and for the pharmaceutical teams that develop them.

Science, part 1 of 3

What Ēnel brings to the science

What peptides are, and what they do in people. The four screens ahead:

  1. The science in plain wordsHow Ēnel writes the science so anyone can read it.

  2. Peptides and proteinsMost peptides are pieces of bigger proteins, and one of them led to three medicines.

  3. Off-target effectsEffects beyond a peptide's target, seen in members' daily data.

  4. Metabolic pathwaysWhat each added pathway changes in daily life.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Science, plain words Live in Ēnsights

We turn the science into content people can digest, and we name the scientists behind it.

Each entry says what a compound is, what it does and what people often get wrong, with the experts for and against it.

Ēnel is built on research, and written to be read.

Papers are written for scientists, and ads are written to sell. Ēnel sits between them and the people who use the products, and closes the gap.

Ēnsights, peptides

GHK-Cu

Grade 2 of 5, thin

  • A copper-binding peptide found in human blood, saliva and urine. Levels fall from about 200 ng/mL at age 20 to about 80 ng/mL by age 60.
  • Discovered by Loren Pickart, UCSF, 1973, in Nature.
  • Key study Leyden, Dermatologic Surgery, 2005, a randomized 12-week trial of a face and eye cream.
  • A partner's new findings can reach members the same way, with the scientists named.Partnership to build

Scientific papersWritten for specialists

Product adsWritten to sell

Clinical studiesWritten for regulators

Ēnel HealthResearch-based and graded 1 to 5, in plain words, with the scientists named

The people who use themMembers, and the teams who make the products

Ēnsights, the Ēnel Health wiki, entry for GHK-Cu, as of 11 November 2026.

Science, shared with the world Partnership to build

We put the scientists behind the science on our Instagram, and their work in front of people everywhere.

A partner's research reaches people in a form they read, understand and pass on.

Their story

Who they are, the question they chose and why it matters to them, told in their own words.

Their research

What they found and how sure it is, in short, plain posts, with their names and their papers linked.

Their reach

Posts people save, share and ask about, so what a lab knows informs people around the world.

See it on Instagram

Science, peptides and proteins

Most peptides people take are pieces of bigger proteins.

Each one is a short chain of amino acids, cut from a longer chain or built on one.

Studying one peptide, α-MSH, has already led to three approved medicines.

Small changes to the same 13 amino acids aimed it at the skin, sexual desire or appetite, and one of the three came from what a tanning study saw in three men.

If BPC-157 leaves the blood within 30 minutes, what keeps its effects going for days?

A piece keeps part of the full protein's job, and its structure decides what it binds and how long it lasts.

  • GHK-CuGHKThree amino acids found in collagen.
  • KPVKPVThe last three amino acids of α-MSH.
  • TB-500LKKTETQA seven-amino-acid piece of thymosin beta-4.
  • BPC-157GEPPPGKPADDAGLV15 amino acids of a protein reported in stomach juice.
  • SemaxMEHFPGPBuilt on a piece of ACTH, with three amino acids added.
  • SemaglutideGLP-1 with two changes and a fatty chain added, which stretches its time in the blood from under 2 minutes to about a week.
α-MSH*SYSMEHFRWGKPVA hormone of 13 amino acids that darkens the skin and curbs appetite.
  • Afamelanotide, MT-1Two amino acids changed so it lasts longer. Sold as Scenesse, for a disorder that makes light painful.Approved 2019
  • Melanotan II, MT-2A short ring built on its core, sold online for tanning. It caused erections in a 1996 study of three men.Not approved
  • Bremelanotide, PT-141What Melanotan II becomes in the body, with one change at its end. Sold as Vyleesi, for low sexual desire in women.Approved 2019
  • SetmelanotideA ring of eight amino acids aimed at the appetite receptor. Sold as Imcivree, for rare genetic obesity.Approved 2020
  • KPVIts last three amino acids, reviewed by FDA for wound healing and inflammation.HHS policy

How their structures relate, what each is used for, and their pathway, in the appendix

BPC-157

<30 min

Its half-life in the blood, in rats, dogs and a two-person pilot

Days

How long its effects are reported to last, from hours to days

  • At the bench, a lab finds the sequence, the structure and what it binds.
  • In people, Ēnel follows each dose and how the member felt every day after it.

Pickart and Margolina, 2018. Dalmasso et al., 2008. Esposito et al., 2012. He et al., 2022. International Journal of Molecular Sciences, 2021, on Semax. Knudsen and Lau, 2019. Ozempic prescribing information.

FDA, 8 October 2019, Scenesse. FDA, 21 June 2019, Vyleesi. FDA, 27 November 2020, Imcivree. Dorr et al., 1996. FDA warning letter on Melanotan II, 2007. Dalmasso et al., 2008.

Review of BPC-157, Pharmaceutics, 2026. He et al., Frontiers in Pharmacology, 2022.

Science, off-target effects Recording live Analysis in development

Members' daily data shows effects beyond a peptide's target that a lab can then test.

An effect seen in people points back to binding and selectivity at the bench.

20

groups of effects are recorded beside each dose day, from digestion and skin to focus and hormones, by product and by person.

Word of mouth

People on tirzepatide and similar drugs say their mood lifted and the constant “food noise” went quiet.

Neither is an approved use of these drugs, and some people report the opposite.

Ēnel Health experience library, 13 November 2026. Arillotta et al., Brain Sciences, 2023. Penn Medicine, 20 November 2025.

Science, metabolic pathways In development

Each newer drug adds one pathway, and members on all three show what each one changes in daily life.

Semaglutide works through GLP-1, tirzepatide adds GIP and retatrutide adds glucagon. Trials report the weight lost at the end, not the days in between.

If GLP-1 drugs followed this path, which other peptides can follow it?

A hormone the body makes, then a version that lasts, then one medicine on more receptors. Three other hormones are on the same path now.

  1. GLP-1Exenatide, from Gila monster venom, in 2005; semaglutide once a week; then tirzepatide and retatrutide on more receptors.Approved
  2. AmylinPramlintide in 2005; cagrilintide once a week; then CagriSema, 22.7% of weight lost in a phase 3 trial, and amycretin.Filed with FDA
  3. OxyntomodulinA gut hormone on GLP-1 and glucagon already; mazdutide, once a week, approved in China in 2025, and survodutide.Approved in China
  4. GLP-2Teduglutide in 2012, for short bowel syndrome; apraglutide and glepaglutide once a week, both in phase 3.Phase 3

Not every hormone follows: drugs built on PYY and GDF15 have added little so far. Members on each drug can show what every added receptor changes, day by day.

Weight lost in trials

  • Semaglutide
    GLP-1GIPGlucagon
    13.7%
  • Tirzepatide
    GLP-1GIPGlucagon
    20.2%
  • Retatrutide
    GLP-1GIPGlucagon
    24.2%

Semaglutide and tirzepatide head to head over 72 weeks, and retatrutide over 48 weeks in its own trial, where blood ketones also rose two to threefold.

What the trials leave out

How each added pathway changes energy, appetite, sleep and heart rate from one day to the next, which members on each of the three drugs log every day.

Aronne et al., New England Journal of Medicine, 2025 (SURMOUNT-5). Jastreboff et al., New England Journal of Medicine, 2023. Sanyal et al., Nature Medicine, 2024.

FDA, exenatide, 28 April 2005, and pramlintide, 2005. Novo Nordisk, REDEFINE 1, New England Journal of Medicine, 2025, and amycretin phase 2. Innovent, mazdutide, NMPA approval 27 June 2025. Boehringer Ingelheim, SYNCHRONIZE-1 and SYNCHRONIZE-CVOT, 2026. Ironwood, apraglutide, April 2025. Zealand, glepaglutide, 2026. PYY1875, phase 2, 2025. GDF15 analogs, review, 2026.

Science, part 2 of 3

New uses and products

Where reports from people can lead.

  1. Peptide discoveryReports from people that pointed to new uses, and how Ēnel finds them.

  2. Product formHow the form of a product decides how people take it.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Science, peptide discovery Partnership to build

What people report on a peptide can point to a new use worth testing.

2013 to 2026

YK-11 to apitegromab

YK-11 raised follistatin, which blocks myostatin, the protein that limits muscle, in mouse cells in 2013, and turned up in a black-market product in 2017. Apitegromab blocks myostatin directly: FDA approved it for spinal muscular atrophy in September 2026, and trials pair it and bimagrumab with GLP-1 drugs to keep muscle.

What Ēnel offers

Ēnel collects the changes people report on each peptide and shows which ones repeat.

1996 to 2019

Melanotan II to bremelanotide

Melanotan II, a tanning peptide, caused erections in a 1996 study of three men. Bremelanotide is what Melanotan II becomes in the body, the same ring with one change at its end, and FDA approved it in 2019 for low sexual desire in women.

Why it matters

Reports like these have pointed to new uses before, as these three cases show.

2023 to 2026

Semaglutide and alcohol

Six people taking semaglutide for weight loss showed fewer signs of alcohol use disorder in 2023. Three trials since then found less drinking on some measures, but not on all.

How it works

A partner's lab tests the mechanism, and a controlled study tests the effect.

Kanno et al., 2013. WADA. Scholar Rock, 11 September 2026. Heymsfield et al., 2026. Pratley et al., 2026. Dorr et al., 1996. Hadley and Dorr, 2006. FDA, 21 June 2019. Richards et al., 2023. Hendershot et al., 2025. Klausen et al., 2026. Schacht et al., 2026.

Science, product form, 1 of 2

How people take a product today shows what a new product needs to solve.

If members skip doses because a vial takes too many steps, a developer can test a ready-to-use pen against the vial.

What Ēnel records about each product

  • The route, amount, schedule, time of day and cycles of days on and off.Live
  • What it is combined with, how long it has been taken, and why a day was skipped.Live
  • The lot, its storage and the day it was mixed.Partnership to build
  • Sequence, formulation and stability data from the developer.Partnership to build

Science, product form, 2 of 2

A product's form decides how people take it.

The same medicine worked nearly three times as often in a new form: in a rescue test, 31% of people gave a full dose of glucagon from the powder kit, and 88% from a ready-to-use pen, which FDA approved in 2019.

Glucagon rescue test, 16 people

Powder kit, mixed during the rescue31%
Ready-to-use liquid pen88%
  • A new form made semaglutide a second product: a daily pill followed the weekly injection, for diabetes in 2019 and for weight loss in December 2025.
  • A form that makes people measure invites mistakes: in 2024, FDA reported dosing errors with compounded semaglutide when people confused milligrams, millilitres and syringe units.

Valentine et al., 2019. Xeris, 10 September 2019. FDA, 20 September 2019. Novo Nordisk, 22 December 2025. FDA, 26 July 2024. Knudsen and Lau, 2019.

Science, part 3 of 3

Sensors and a first study

What a lab and Ēnel can build and test.

  1. Case study 1: wearables and sensorsSensors worn every day, a sweat sticker on the shelf, and what the next ones need.

  2. Sensor discoveryHow members' data points a sensor to the molecule worth measuring.

  3. Proposed case study 2: a first joint studyKetones in people on retatrutide.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Science, case study 1: wearables and sensors

Health sensors worn every day are now a billion-dollar business, and the next ones need evidence from people.

One sweat sticker for hydration reached the shelf; the sensors behind it still need evidence from people.

Case study: Oura, a ring that reads sleep, heart rate and temperature

Revenue, 2024$500M
Revenue, 2025About $1B
Revenue, 2026, expectedClose to $2B

About 5 million paying members, and about 85% still subscribed a year later.

What Oura says comes next

expand access, build clinical evidence, and deepen integrations with health plans, employers, and care providers

Oura, filing to go public, September 2026.

On the shelf: a sticker that reads sweat for hydration

Gatorade Gx Sweat Patch

Made with Epicore Biosystems and sold since March 2021. Worn once during exercise, it fills with sweat through fine channels that change colour, and a photo in the Gx app reads it.

What it reads

Sweat rate, fluid lost and sodium lost in one session, which the app turns into how much to drink. It is still sold in 2026.

Still in the lab: sensors that read sweat

  1. 2018

    A wearable sensor read caffeine in sweat, and the level rose with the dose.

  2. 2024

    A gold-nanoparticle patch read estradiol in sweat and tracked blood levels.

  3. 2026

    A sticker on a drinking cup read vitamin C from fingertip sweat, at UC San Diego.

What they lack, a 2026 review says: “long-term on-body testing … and large-scale clinical validation”.

Oura, S-1 filing, 3 September 2026, as reported by TechCrunch.

Gatorade, Gx Sweat Patch, launched 1 March 2021 (CNBC), and gatorade.com, 16 November 2026. Tai et al., 2018. Ye et al., 2024. UC San Diego, 25 February 2026. Mondal and Saikia, Biosensors, 2026.

Science, sensor discovery Partnership to build

Ēnel gathers the data that points a sensor to the molecule worth measuring.

Apple built its blood pressure alerts from studies of more than 100,000 people and won FDA clearance in September 2025.

  1. 1

    The dataDaily check-ins, wearables and phone checks of strength, balance and reaction time.LiveFood photos and a home saliva kit for a reference reading.Proposed

  2. 2

    The algorithmA model learns which molecule follows the change people feel.

    In development
  3. 3

    The wearableA partner builds a sensor for that molecule into a wearable, and Ēnel members test it in daily life.

    Partnership to build

Apple, 9 September 2025 (validated in over 2,000 people). MobiHealthNews, 15 September 2025.

Science, proposed case study 2: a first joint study Proposed

Can a ketone sensor show, day by day, what drives ketones up in people on retatrutide?

A first joint study with a lab. In a trial, retatrutide raised blood ketones two to threefold at the higher doses, but the trial measured them only at visits.

Ēnel's side

  • Members on retatrutide and other incretin drugs log each dose, meals by photo, fasting, alcohol and sleep.
  • Every sensor reading gets those labels, so models can find what drives a rise.
+

The lab's side

  • The lab supplies a research ketone sensor and checks it against blood at the bench.
  • Abbott's glucose and ketone sensor is authorized only for people with diabetes.
=

Together

  • The first day-by-day ketone curves in people on these drugs, labelled with what happened that day.
  • Go or no-go at three checkpoints: the protocol is approved, enough members join and stay, and the agreed analysis is run.

Sanyal et al., Nature Medicine, 2024 (retatrutide, phase 2a). Abbott, 25 August 2026. Ketonix. Lumen, Lumen and keto. Biosense closure, September 2024.

Route 2 of 3, manufacturing and commercial products

Six peptides can be compounded under a draft HHS policy, and data from people is what they lack.

This route is for 503A compounding pharmacies, the companies that develop and sell peptide products, the suppliers that serve them, and the telehealth firms that prescribe and ship them.

Manufacturing and commercial products, part 1 of 3

The policy

What changed, and what is still missing. The four screens ahead:

  1. The shiftPeptide policy, step by step, since 2023.

  2. The HHS draft policyThe six peptides pharmacies may now compound.

  3. The work leftWhat each pharmacy still has to do, and where Ēnel helps.

  4. The gapWhy FDA's reviewers still recommend against all six.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Manufacturing and commercial products, the shift

Peptide policy is moving faster every few months.

Fifteen months passed between the first two steps. In 2026, a new step came every two to three months.

  1. Sep 2023

    FDA restricts BPC-157 and other peptides (Category 2).

  2. Dec 2024

    First committee review. FDA proposes against CJC-1295.

  3. Feb 2026

    The HHS Secretary expects about 14 peptides to open.

  4. Apr 2026

    12 peptides leave Category 2.

  5. Jul 2026

    The committee votes for 6 of 7.

  6. Oct 2026

    HHS draft policy for six peptides.

Manufacturing and commercial products, the HHS policy

A draft HHS policy lets pharmacies compound six peptides.

But each pharmacy still has work to do before the first vial ships.

Ēnel can carry the part of that work that needs people.

Why do FDA's reviewers still recommend against all six?

Since 30 October 2026, 503A pharmacies may compound them under 10 conditions, and the six stay unapproved and off the 503A Bulks List.

Every condition falls on the compounder, and some need tests that only a lab can run.

Three of the five depend on what happens after the vial leaves the pharmacy.

Ēnel follows each person at home, by product and lot, and a study with the pharmacy's patients turns that into evidence.

HHS asks for reports of serious adverse events and relied on documented historical use, and both come from the people who take the product.

Three of their four reasons ask for data from people, the part Ēnel can carry.

The HHS draft policy, Oct 2026

BPC-157

TB-500

KPV

MOTS-c

Semax

Epitalon

Each source must be CGMP-registered, with a certificate of analysis.

  • Sourcing
  • The supply chainĒnel reads the lot from each label photo, so each outcome traces back to its lot and maker.Live
  • Sterility and stabilityĒnel would ask when each vial was mixed and how it was stored, beside how the person responds.Partnership to build
  • ReportingMembers report side effects as they happen, tied to the product and its lot.Live
  • Oral products

Hover over each oneTap each one for what it asks.

Sourcing and absorption in people are lab work. For the other three, a study with the pharmacy's patients, from the first vial, brings it together: clinical studies.

  • Side effects as they happen
    Members report how they feel each day, tied to the product and its lot.Live
  • Historical use
    Dated logs of what each member took, how much and for how long. FDA said this was missing for BPC-157.Live
  • Signals to the pharmacy
    A serious event a member reports reaches the pharmacy, so it can report to FDA and the state.Partnership to build
  • Outcomes for the use FDA reviewed
    Real-world safety and effectiveness, by product and lot.Partnership to build

Characterization, sterility and CGMP are lab work, and Ēnel does not replace them.

FDA's criterionFDA's wordsWhat can answer it Characterizationnot well-characterizedThe lab's own tests. Safetythe lack of any human dataSide effects as they happenLive Effectivenesslack of evidence to evaluate the effectivenessOutcomes for the use FDA reviewedPartnership to build Historical useinsufficient information availableHistorical useLive

The American Medical Association asked HHS and FDA on 9 November 2026 to rescind the policy.

Frier Levitt, 16 April 2026. FDA, 4 December 2024. PharmExec and BMJ, July 2026. Federal Register 2026-22192.

Federal Register 2026-22192. Holland & Knight, 4 November 2026.

Federal Register 2026-22192. Frier Levitt, 17 February 2025. Wolters Kluwer, 28 February 2025, on USP <797>.

Federal Register 2026-22192. Holland & Knight, 4 November 2026. FDA briefing document on BPC-157, July 2026.

FDA briefing documents for the committee, July 2026. The safety and effectiveness lines are from the KPV review, and the historical use line is from the BPC-157 review. Medical Daily, 12 November 2026.

Manufacturing and commercial products, part 2 of 3

How Ēnel would achieve this

How data from people reaches FDA.

  1. How evidence reaches FDAThe three points where a partner can bring data.

  2. Lot trackingEach person's outcome tied to a lot and its product claims.

  3. StabilityHow each vial is handled, beside how people respond.

  4. Efficacy testingOutcomes for the use FDA reviewed.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Manufacturing and commercial products, the partnership

Lot trackingStabilityEfficacy testingLivePartnership to build

A partner can bring Ēnel's data from people to FDA at three points.

The partner decides what to submit, and submits it in its own name.

At each point, a partner can bring three kinds of evidence from people.

Lot tracking runs today, and stability and efficacy testing are built with a partner.

Lot tracking ties each person's outcome to a lot and its product claims.

HHS relied in part on lot-specific data, and it may revisit the policy if a product quality issue arises.

Ēnel would capture how each vial is handled, beside how people respond.

The check-in would ask when a vial was mixed, how it was stored and how long it was in use.

FDA judges effectiveness for a named use.

Each study is observational and measures real-world effectiveness.

1

Nomination

Compounders and others can still nominate a substance for the 503A Bulks List, with supporting information.

2

The committee

Comments sent to the meeting docket in time go to the committee, and nominators present at the meeting.

3

The proposed rule

Anyone can comment on a proposed rule with scientific information and clinical data.

FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence.

HHS, Federal Register, 30 October 2026.

Where the evidence goes

NominationThe committeeThe proposed rule

What it carries, for each personLive

  1. 1

    OutcomeDaily check-ins and biometrics.

  2. 2

    DoseTaken taps on the day.

  3. 3

    ProductMatched from the label photo.

  4. 4

    LotThe lot number, read from the label.

  5. 5

    Product claimsWhat the label and the certificate of analysis claim for that lot.

  • In the lab, stability is measured under set conditions.
  • Together, a partner can see whether response changes as a vial ages or with storage.

USP <797> allows up to 28 days of use after a preserved multiple-dose compounded vial is first punctured, when preservative testing supports it. That is a sterility limit, and stability in use is a separate question.

PeptideUse FDA reviewedWhat a study could measure EpitalonInsomniaSleep and HRV from wearables. TB-500 and KPVWound healingPhotos of the wound over time. SemaxMigraineHeadache days from the daily check-in.

FDA, Bulk Drug Substances Used in Compounding, 14 May 2026. Federal Register 2026-07361. Buchanan Ingersoll & Rooney, 18 August 2026.

Holland & Knight, 4 November 2026. Federal Register 2026-22192.

US Pharmacist, 29 December 2022.

Uses from FDA's notice for the July 2026 meeting, Federal Register 2026-07361. Effectiveness is criterion 3 in 21 CFR 216.23.

Manufacturing and commercial products, part 3 of 3

The studies

Where a partner can start.

  1. Clinical studiesOne study across every state a pharmacy serves.

  2. First studiesTwelve peptides, and the first studies we propose.

  3. Topical GHK-CuA different market: skin care.

  4. TelehealthA different partner: telehealth firms.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Manufacturing and commercial products, clinical studies Partnership to build

One study can follow a pharmacy's patients in every state it serves.

A 503A pharmacy needs a license in each state it ships to. One protocol and one consent follow its patients into every one of them, with no sites to open.

CaliforniaAlaskaOregonWashingtonNevadaIdahoArizonaUtahMontanaHawaiiWyomingNew MexicoColoradoNorth DakotaSouth DakotaTexasNebraskaKansasOklahomaMinnesotaIowaMissouriArkansasLouisianaWisconsinIllinoisMississippiIndianaMichiganAlabamaTennesseeKentuckyOhioGeorgiaWest VirginiaFloridaSouth CarolinaNorth CarolinaVirginiaPennsylvaniaMarylandNew YorkDelawareNew JerseyVermontConnecticutNew HampshireMassachusettsRhode IslandMaineFlorida · day 1 · joinedCalifornia · day 3 · taken, lot 24A17Colorado · day 9 · nausea 2 of 10Texas · day 12 · sleep 6 of 10Ohio · day 14 · skipped, travellingNew York · day 28 · finished

The check-ins are an illustration of one study, not member data. The same study design can run in other countries later.Next

Health Law Alliance, 15 August 2026.

Manufacturing and commercial products, first studies Proposed

FDA's committee reviewed seven peptides in July 2026, each for one use, and backed six.

The use beside each is the one FDA reviewed it for.

Five more go before the committee by February 2027.

GHK-Cu, LL-37, Dihexa acetate, PEG-MGF and Melanotan II have not been reviewed yet.

  • BPC-157
    Ulcerative colitisHHS policy
  • TB-500
    Wound healingHHS policy
  • KPV
    Wound healing and inflammatory conditionsHHS policy
  • MOTS-c
    Obesity and osteoporosisHHS policy
  • Semax
    Cerebral ischemia, migraine and trigeminal neuralgiaHHS policy
  • Epitalon
    InsomniaHHS policy
  • Emideltide (DSIP)Not recommended
    Opioid withdrawal, chronic insomnia and narcolepsy
  • GHK-Cu*
    Not reviewed yet, due at the next committeeBy February 2027
  • LL-37 (cathelicidin)
    Not reviewed yet, due at the next committeeBy February 2027
  • Dihexa acetate
    Not reviewed yet, due at the next committeeBy February 2027
  • PEG-MGF
    Not reviewed yet, due at the next committeeBy February 2027
  • Melanotan II
    Not reviewed yet, due at the next committeeBy February 2027

* GHK-Cu also has topical uses, and as copper tripeptide-1 it is sold today in skin care without FDA approval.

Federal Register 2026-07361. FDA briefing documents, July 2026. BMJ, 28 July 2026. Frier Levitt, 16 April 2026. Medscape, 28 July 2026, on the next five.

Manufacturing and commercial products, first studies Proposed

Our first study of each peptide would follow people who take it for the use FDA reviewed.

BPC-157 in people with ulcerative colitis, for example, over one course, with the lot recorded for each vial.

The partner brings

  • Product made under the HHS conditions.
  • Each batch's lot and its product claims.
+

Ēnel brings

  • The study design, consent and daily check-in for the partner's patients.
  • Daily outcomes and biometrics, ready to analyse.
=

Together

  • Outcomes in people, traced to each lot.
  • Evidence the partner can submit to FDA.

Manufacturing and commercial products, a different market

Topical GHK-Cu

For skin care brands. One of the eight peptides is already sold as a cosmetic, with no FDA approval needed.

Topical GHK-Cu, for skin care brands Proposed

GHK-Cu is already sold in skin care, where it needs no FDA approval.

FDA defines a cosmetic by its use. A cream that claims to change how skin looks is a cosmetic, and one that claims to treat a condition is a drug.

How people use GHK-Cu shows a skin care brand what to make next.

In ten months, copper peptide went from the 94th to the 26th most talked-about skin care ingredient on Instagram, and people now inject it as well as apply it.

  • On the shelf
    Copper tripeptide-1, its label name, is sold today in creams and serums by mainstream brands such as Naturium.
  • The rules
    No FDA approval is needed before sale. Under MoCRA the maker registers, lists each product and reports serious adverse events within 15 business days.
  • The evidence
    In 71 women, a GHK-Cu face cream used for 12 weeks increased skin density and thickness and reduced fine lines and wrinkle depth. A 2024 review still found few clinical studies.
  • What a study could measure
    Skin photos and the snap-back test over time, beside what members apply and any reaction they report.
What people doWhat could sellWhat Ēnel tracks They inject it from online sellers, for skin and hair, though one clinician sees creams work much better.A topical that reaches deeper, for the people who now inject.The route, the dose, and skin and hair photos, by route. They struggle to fit it beside retinoids, vitamin C and acids, and many alternate mornings.A routine sold as one, made to be used together.What each member applies, at what time, and any reaction. They move it to the neck and décolleté, as firming without a needle.Formats for the neck and body.Where it is applied, and photos over the weeks.

Members can already log GHK-Cu in Ēnel, alone or in blends such as GLOW, with its route, dose and schedule. These patterns come from public reporting and posts, not from Ēnel member data.

NPR, 7 September 2026. GLOWCAST by WHOTAG, 17 July 2026, on Instagram from August 2025 to June 2026. Skin care threads on Reddit, 2024 to 2026, and Deciem's guidance on copper peptides.

FDA on cosmetics and on MoCRA. Pickart and Margolina, 2018. Naturium, 7 October 2026, citing Mortazavi et al., 2024.

Manufacturing and commercial products, a different partner

Telehealth

For telehealth firms. They prescribe online and ship from 503A pharmacies like those under the HHS policy, so the same lot tracking and studies apply.

Telehealth, for telehealth firms

A telehealth prescribes online and mails the product to the door.

Once the product ships, a telehealth sees little of what follows.

Ēnel gives a telehealth one place to run studies with its patients.

About one in six people who have taken a GLP-1 got it online, and telehealth firms now plan to offer peptides.

Few patients who start online are still on their treatment a year later, and few sellers see them by video before they prescribe.

Patients check in from home each day, and the telehealth sees side effects, symptoms and how each product is used.

  1. 1

    IntakeThe person fills in an online form and a medical history questionnaire.

  2. 2

    ReviewA doctor, nurse practitioner or physician assistant reviews it, often with no live visit unless state law requires one.

  3. 3

    PrescriptionThe prescription goes to a partner pharmacy, often a mail-order 503A compounding pharmacy, the kind the HHS policy covers.

  4. 4

    DeliveryThe product is mailed home, so the person never visits a pharmacy.

  5. 5

    RefillsRefills arrive by mail, and the person messages a care team about problems.

12%

of 4,535 people who started an online semaglutide weight-loss service were still ordering it and sending their data a year later.

13 of 49

online GLP-1 sellers asked for a video visit before they prescribed, in a test reported in JAMA. What follows the prescription went unmeasured.

with limited published studies, we draw primarily from clinical experience from the last decade.

Andrew Dudum, Hims & Hers, on peptides, 29 October 2026.

  • Side effects and symptoms
    A daily check-in by text, voice or video, with taps from 1 to 10 and a body map of 26 places.Live
  • Product use
    Taken taps on the day, the product matched from a label photo, and each person's dosing schedule learned by our models.Live
  • Studies
    A study of the telehealth's own products with its patients, with one protocol and one consent in every state.Partnership to build
  • Reports
    Outcomes by product and lot, and the reasons people stop, for the telehealth's clinicians.Partnership to build

Ēnel does not replace the clinician, so a patient who feels unwell still contacts the care team.

The same tools a pharmacy uses:Lot trackingWhat Ēnel carriesClinical studies

KFF Health News, 1 June 2026. KFF Health Tracking Poll, 14 November 2025. Hims & Hers, 29 October 2026.

Talay et al., Diabetes, Obesity and Metabolism, 2026 (a digital weight-loss service in Germany). Chetty et al., JAMA, 2026, as reported by AJMC. Hims & Hers, 29 October 2026.

Route 3 of 3, academics and research

Run real-world studies with people who already check in every day.

This route is for university and hospital research groups, study designers and data analysts.

Research, part 1 of 3

The study

How an Ēnel study is built and run. The three screens ahead:

  1. How a study runsFrom the claim back to the first check-in.

  2. Studies redesignedHow we changed the way a study collects evidence.

  3. Video check-insMembers answer a study's questions on video from home.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Research, how a study runs Live

We build each study from the end to the beginning, starting with the claim and the evidence that would lock it.

A locked claim is Ēnel's own finding, not an FDA-approved claim.

  1. 1

    The claimA member brings a claim, or it comes from the published science.

  2. 2

    The studyThe team sets the question, the measures and who can join, then opens the study.

  3. 3

    The evidenceMembers check in each day, and their answers fill the study.

  4. 4

    The claim lockedThe team accepts or declines the claim from the evidence.

Claim status in the Ēnel Health app, New, Studying, then Accepted or Declined, as of 15 November 2026.

Research, studies redesigned

We redesigned how a study collects evidence.

Rounds run 7 to 28 days with rolling enrolment, and seven study designs are open today.

Traditional studyĒnel study WhereClinic visitsAt home, on the phone, anywhere in the US How oftenA few visitsEvery day MeasuredQuestionnaires at visitsCheck-ins beside biometrics, voice and short games that follow validated tests Compared withGroup averagesEach person's own baseline, then the cohort CommunityEach person takes part aloneMembers see how others like them respond and what they report

Research, video check-ins

Members answer a study's questions in a short video from home.

Our models pull out what was taken, how much and how it felt, and members without AI permission check in by text.

The average time someone travels to a clinical trial is about two hours.

Jeremy Price, Senior Director and Decentralized Trial Lead, Pfizer.

Half

Pfizer set out to remove about half of the in-person visits in its trials.

40%

AstraZeneca reports up to 40% fewer in-person visits in some trials with digital tools.

Pfizer, The Clinical Trial Anywhere model, 9 April 2025. AstraZeneca, Patient commitment in R&D, August 2026. A video answer is study data, not a validated clinical measure.

Research, part 2 of 3

The people

Who joins, who stays, and what is real.

  1. Recruitment and dropoutGetting the right people in, and keeping them to the end.

  2. Keeping members inSix ways Ēnel keeps members in a study.

  3. Placebo and confoundersSeparating placebo effects from real ones.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Research, recruitment and dropout

A study works only if the right people join and stay to the end.

Ēnel works to keep each member in the study to the end.

Members join a study from the app they already check in with.

In eight remote studies of more than 100,000 people, half had stopped by day 5.5, and a referral or a friend changed that most.

Trials stopped early because too few people joined, of 1,0179.9%
People still in a remote trial at six months, of 17,82580.4%
People who stayed to the end of that trial68.5%
  • A skipped day is saved with its reason, so each drop has a cause.Live
  • A partner sees how many people joined, stayed and finished, step by step.Partnership to build

Partners refer their patients

A clinician's referral added 40 days to how long people stayed in remote studies.

Partnership to build

Members are not alone

Members see others like them. People recruited with friends finished 95% of the time, against 76% alone.

Live

Results as they come

Members see their then and now beside the cohort. Only 5.8% of Project Baseline participants opted out of their results.

Live

We spot who may stop

Skipped days and their reasons flag who may leave, so the team reaches out first.

Built, filling with data

We meet people where they talk

Across 23 studies, social media ads recruited about twice as many people per dollar.

Live

Short check-ins

A check-in takes under 2 minutes, with at most six study questions a day.

Live

Kasenda et al., JAMA, 2014 (trials approved in Switzerland, Germany and Canada, 2000 to 2003). Zwiers et al., Mayo Clinic Proceedings: Digital Health, 2025 (the COVID-RED trial).

Pratap et al., npj Digital Medicine, 2020. Wing and Jeffery, 1999. Project Baseline, PLOS ONE, 2021. Tsaltskan et al., 2023.

Research, placebo and confounders

Our studies are designed to separate placebo effects from real ones.

Sleep, HRV and resting heart rate check what people report, and voice and reaction time add signals people cannot easily steer.

30% of patients on placebo will have a self-reported response or even objective response

Dr. Brian Lee, FDA advisory committee member, July 2026.

A bad night or an illness shows in the data before it is blamed on a product.

NBC News, 23 July 2026. A study that must measure the placebo effect itself also needs a comparison group.

Research, part 3 of 3

At scale

Many countries, and what researchers get today.

  1. Global studiesOne protocol across many countries.

  2. What researchers get todayWhat any scientist can use now.

They are on the left now. Click one to jump to it, or keep scrolling.Each one is also in the route's table of contents. Keep scrolling to begin.

Research, global studies

One protocol can run in many countries, with each country's own approvals.

Roche's global head of regulatory describes decentralised trials as letting every patient take part, wherever they live.

One protocol

Shared by every country

The protocolQuestions in each languageThe data modelQuality checks

The United StatesLive

  • Ethics approval
  • A local investigator
  • Consent
  • Privacy rules
  • Data transfer

Set in each country

Roche, A rare disease, a first in virtual clinical trials (Michelle Rohrer). ICH E6(R3) Good Clinical Practice, adopted 6 January 2025.

Research, what researchers get today

All scientists can work with Ēnel's studies now.

A research group designs one study with us, and we run it with members across the US.

  • A study design view for scientists, with every running study and how each one collects data.Live
  • Read-only voice and face analysis, with trends, quality checks and what each measure means.Live
  • Coded research data for named analysts, with the owners of each analysis listed.Live
  • One protocol and one dataset, published whatever the result.Proposed
  • An IRB review of our studies is under way.In review

Research, what we ask of you Partnership to build

Bring us one question. Our members answer it every day, and the world sees your work.

We ask a research group for one study, and we give its work a place where people read it.

You bring

  • A question that matters to your field.
  • The study design, your ethics review and your analysis.
+

Ēnel brings

  • Members across the US who check in every day.
  • One protocol and one consent in every state.
=

The world sees it

  • One dataset, published whatever the result, with your name on it.
  • Your study in Ēnsights in plain words, open to everyone, and shared with our members and on our Instagram.

Start with one question

Projecting into the future

What runs today, what is in progress, and the outcomes it leads to.

1Today

  • Members check in daily by text, voice or video.
  • Our models measure the voice, and the face for members who say yes.
  • Studies run at home, anywhere in the US.
  • Lot tracking links each outcome to its lot and to the product claims.
  • Ēnsights holds 1,771 graded entries.

2In progress

  • The first studies with a lab, a pharmacy and a research group.
  • An IRB review of the study protocol.

3Outcomes

  • Peptide discovery, from what members report and a partner's lab tests.
  • Protein discovery, finding active fragments and breakdown products with structure labs.
  • Biosensor investigation, with members testing partners' sensors in daily life.
  • Metabolic pathways, traced from the signals that move together.
  • New product forms, tested against the old ones in people.
  • Prediction of who will benefit and who will stop.
  • One protocol running in many countries.

Limits

Each part of this plan has a limit, and a way we handle it.

An IRB review is under way, and members choose what they share.

  • The data shows links, not causes: members choose what they take, so we use it to choose the controlled test worth running.
  • Peptides bought online vary in identity and purity, so a weak response may come from the vial.
  • Ēnel collects no samples yet, no blood, saliva or sweat, so any measure that needs one comes from a partner.
  • Members opt in, so each finding is reported for the cohort it comes from.
  • Rare effects need many members on the same product, so we start with GLP-1 drugs.
  • FDA may give observational data less weight than a controlled trial, and lot capture needs a readable lot number.

Join us

Ēnel is a platform you can use too: bring a question, a product or a study, and we will build it with you.

The next step is a 45-minute meeting in La Jolla to choose the question.

  • JeffFounderjeff@enelhealth.comEmailGmail
  • SabrinaChief Scientistsabrina@enelhealth.comEmailGmail
  • CarolineData Scientistcaroline@enelhealth.comEmailGmail

People who want to take part in a study join as members at enelhealth.com. Ēnel observes and does not recommend products, and does not sell peptides or give medical advice.

Our advisors

Nine advisors work with us on the science and the business.

Six advise on the science and three advise on strategy.

Scientific advisors

  • David Adams, Ph.D.Study design and methodologies
  • Portrait of Asif Shakeel, Ph.D.Asif Shakeel, Ph.D.Machine learning and modeling
  • Portrait of Phillip Dickinson, M.D.Phillip Dickinson, M.D.Clinical and surgical
  • Portrait of J. Scott Overcash, M.D., FACEPJ. Scott Overcash, M.D., FACEPClinical design
  • Ravi Kumar, M.D.Evidence integrity
  • Portrait of Maureen CurranMaureen CurranResearch operations

Strategic advisors

  • Portrait of Wajdie AhmadWajdie AhmadBusiness strategy and fundraising
  • Portrait of Brent BackhausBrent BackhausPlatform architecture
  • Portrait of James ChristopherJames ChristopherBrand experience and go-to-market

Names and roles as listed on the About page of enelhealth.com.

Appendix

The detail behind the pages.

The science, the models and the tests in more depth, for anyone who wants it.

Appendix, the melanocortin family

Every peptide in this family keeps the same four amino acids, and each change moves where it acts.

One hormone, five receptors, and a medicine for three of them.

Lined up on the core they share

  1. α-MSHThe body's own, 13 amino acids

    SYSMEHFRWGKPVNH2
  2. Afamelanotide, MT-1Two swapped, so it lasts longer

    SYSNleEHdFRWGKPVNH2
  3. Melanotan II, MT-2Cut to seven and closed into a ring

    NleDHdFRWKNH2
  4. Bremelanotide, PT-141The same ring, with an acid at its end

    NleDHdFRWKOH
  5. SetmelanotideA ring of eight, closed by a sulfur bridge

    RCdAHdFRWCNH2
HThe core, His, Phe, Arg and TrpKChanged from α-MSHdFA mirror-image amino acid, harder to break downClosed into a ring

How the appetite pathway runs

  1. LeptinMade by fat, it turns on POMC neurons
  2. POMC neuronsIn the arcuate nucleus, POMC is cut into α-MSH
  3. MC4RIn the paraventricular nucleus; AgRP blocks itSetmelanotide and bremelanotide act here
  4. Less hungerAnd more energy used

POMC, PCSK1 and LEPR deficiency break this chain before MC4R. Setmelanotide acts at MC4R itself, past the break.

  • MC1RPigment cells of the skinAfamelanotide (Scenesse), for light that is painful in erythropoietic protoporphyria. Melanotan II is sold online for tanning.
  • MC2RThe adrenal gland, for ACTHNone of the four.
  • MC3R, MC4RThe brain: appetite and energySetmelanotide (Imcivree), for obesity from POMC, PCSK1 or LEPR deficiency and Bardet-Biedl syndrome. Bremelanotide (Vyleesi), for low sexual desire in women.
  • MC5RGlands, such as the oil glands of the skinNone approved.

FDA labels: Scenesse (afamelanotide), 8 October 2019; Vyleesi (bremelanotide), 21 June 2019; Imcivree (setmelanotide), 27 November 2020. Al-Obeidi et al., Journal of Medicinal Chemistry, 1989 (Melanotan II).

Cowley et al., Nature, 2001. Chen et al., Cell, 1997 (MC5R). FDA labels: Scenesse, 2019; Vyleesi, 2019; Imcivree, 2020, and Bardet-Biedl syndrome, June 2022.

Appendix, prediction In development

Each day of data improves what our models can predict.

Response

Who will benefit, predicted from the first weeks.

Early warning

Patterns that come before a reported side effect.

Product signal

When one product behaves differently from others of its kind.

Combinations

Which products work well together, and which work against each other.

Lasting effect

How long a change holds after someone stops a product.

Drop-off

Who is likely to stop, from early skipped days and the reasons members give.

Models train only on coded data that members chose to share.

Appendix, games

Three short games follow published tests of the mind.

Members play them on the phone inside a study.

Odd One Out

It measures reaction time. It is our own build of TestMyBrain's Choice Reaction Time, scored by the median time of the correct answers.

Symbol Match

It measures processing speed in 45 seconds. It is our own build of TestMyBrain's Digit Symbol Matching.

Phone number game

It measures short-term memory. Members remember a string of digits and type it back, as in a forward digit span.

Live

TestMyBrain, The Many Brains Project. Singh et al., J Med Internet Res, 2023.

Appendix, body checks

Four weekly body checks follow published tests of the body.

Members choose which checks to add, and the phone counts or times each one.

Chair stand

It measures leg strength. It follows the 30-second chair stand in CDC STEADI, and the phone's motion sensor counts each stand.

Built, not on yet

One-leg stand

It measures balance. It follows the balance test in CDC STEADI, with a forearm plank as a second choice.

Built, not on yet

Push-ups

It measures upper body strength. Members do one set, and the screen counts each push-up.

Live

Snap-back

It times how fast the skin on the back of the hand settles after a pinch.

Live

CDC STEADI 30-second chair stand and balance test.

Sources

Every fact on these screens, with its source.

  1. McKinsey & Company. Future of Wellness survey, 2025. mckinsey.com/~/media/mckinsey/email/genz/2025/06/2025-06-03b.html
  2. Roche. Roche to acquire Flatiron Health. 15 February 2018. roche.com/media/releases/med-cor-2018-02-15
  3. Axios, 14 June 2024. axios.com/2024/06/14/ex-groupon-ceo-ipo-precision-medicine-tempus-ai
  4. Reuters, 5 June 2024. reuters.com/markets/deals/tempus-ai-seeks-up-61-bln-valuation-us-ipo-2024-06-05
  5. Ēnel Health. Forum analysis of four peptide and GLP-1 forums, 2011 to 2026, as of 13 November 2026 (internal).
  6. Ēnsights, the Ēnel Health wiki. Count of entries on 13 November 2026. atlas.enelhealth.com
  7. NBC News. FDA panel, with ties to the peptide industry, recommends easing restrictions on four of the compounds. 23 July 2026 (Dr. Brian Lee quote). nbcnews.com/health/health-news/peptides-restrictions-ease-fda-panel-recommend-bpc-157-scientists-rcna588879
  8. Fagherazzi G, Fischer A, Ismael M, Despotovic V. Voice for health: the use of vocal biomarkers from research to clinical practice. Digital Biomarkers, 2021, 5(1):78. doi.org/10.1159/000515346
  9. Rodrigo I, Duñabeitia JA. Listening to the mind: integrating vocal biomarkers into digital health. Brain Sciences, 2025, 15(7):762 (stress, depression and generalized anxiety). doi.org/10.3390/brainsci15070762
  10. FDA. Guidance Recap Podcast: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (Beth Kunkoski, Office of Medical Policy). fda.gov/drugs/guidances-drugs/guidance-recap-podcast-digital-health-technologies-remote-data-acquisition-clinical-investigations
  11. Ēnel Health. Claim status in the app (New, Studying, Accepted or Declined), as of 15 November 2026 (internal).
  12. Linse S, Härdig Y, Schultz DA, Dahlbäck B. A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries. J Biol Chem, 1997, 272(23):14658. jbc.org/article/S0021-9258(19)62443-9/fulltext
  13. Glass JR, Dickerson JC, Schultz DA. Enzyme-mediated individual nanoparticle release assay. Analytical Biochemistry, 2006, 353(2):209. doi.org/10.1016/j.ab.2006.03.020
  14. Vasireddi N et al. BPC-157 review (35 of 36 studies preclinical, 1 in people). HSS Journal, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12313605
  15. Ēnel Health. Experience library (20 groups of effects) and what members record about each thing they take: route, amount, schedule, cycles, time of day, combinations and skipped days. As of 13 November 2026 (internal).
  16. Kasenda B et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA, 2014, 311(10):1045 (101 of 1,017 trials discontinued for poor recruitment, 9.9%). europepmc.org/article/MED/24618966
  17. Zwiers LC et al. Increasing retention in a large-scale decentralized clinical trial: learnings from the COVID-RED trial. Mayo Clinic Proceedings: Digital Health, 2025, 3(4):100264 (17,825 participants; 80.4% at six months, 68.5% to the end). pmc.ncbi.nlm.nih.gov/articles/PMC12514562
  18. Roche. A rare disease, a first in virtual clinical trials (Michelle Rohrer quote). roche.com/stories/virtual-clinical-trials-rare-disease
  19. Pfizer. The Next Era of Decentralized Clinical Trials: The Clinical Trial Anywhere Model (Jeremy Price quote). 9 April 2025. pfizer.com/news/articles/the_next_era_of_decentralized_clinical_trials_the_clinical_trial_anywhere_model
  20. AstraZeneca. Patient commitment, R&D (in-person visits reduced by up to 40% in some trials). August 2026. astrazeneca.com/r-d/patient-commitment.html
  21. ICH. E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025. database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf
  22. Arillotta D et al. GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 2023, 13(11):1503. doi.org/10.3390/brainsci13111503
  23. Penn Medicine, Penn Today. Tirzepatide may only temporarily suppress brain activity involved in “food noise”. 20 November 2025 (Casey H. Halpern). penntoday.upenn.edu/news/penn-medicine-tirzepatide-may-only-temporarily-suppress-brain-activity-involved-food-noise
  24. Holt RIG. Detecting growth hormone misuse in athletes. Indian Journal of Endocrinology and Metabolism, 2013. pmc.ncbi.nlm.nih.gov/articles/PMC3830297
  25. Kanno Y et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull, 2013, 36(9):1460. pubmed.ncbi.nlm.nih.gov/23995658
  26. American Diabetes Association. New GLP-1 therapies enhance quality of weight loss by improving muscle preservation (BELIEVE: bimagrumab with semaglutide; a continuous phenylalanine sensor). 23 June 2025. diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0
  27. Pratley RE et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss (EMBRAZE). Nature Medicine, 2026. doi.org/10.1038/s41591-026-04440-4
  28. World Anti-Doping Agency. Synthesis, clean-up and mass spectrometric characterization of both YK-11 metabolites (YK-11 first detected in a black-market product in 2017; not approved for humans). wada-ama.org/en/resources/scientific-research/synthesis-clean-and-mass-spectrometric-characterization-both-yk-11
  29. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. pubmed.ncbi.nlm.nih.gov/8637402
  30. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization (PT-141 as a melanotan II analog). Peptides, 2006, 27(4):921. pubmed.ncbi.nlm.nih.gov/16412534
  31. FDA. Vyleesi (bremelanotide) multidisciplinary review, NDA 210557 (approved 21 June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women). accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
  32. Richards JR et al. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J Clin Psychiatry, 27 November 2023. psychiatrist.com/jcp/decreased-alcohol-use-disorder-symptoms-with-semaglutide-for-weight-loss-a-case-series
  33. Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 2025. pubmed.ncbi.nlm.nih.gov/39937469
  34. Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. The Lancet, 2026. pubmed.ncbi.nlm.nih.gov/42070571
  35. Schacht JP et al. Oral semaglutide for alcohol use disorder: a randomized clinical trial. 2026. pubmed.ncbi.nlm.nih.gov/42522065
  36. Heymsfield SB et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE). Nature Medicine, 2 March 2026. doi.org/10.1038/s41591-026-04204-0
  37. Valentine V et al. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technology and Therapeutics, 2019. pmc.ncbi.nlm.nih.gov/articles/PMC6708285
  38. Xeris Pharmaceuticals. FDA approval for Gvoke, the first ready-to-use stable liquid glucagon. 10 September 2019. investors.xerispharma.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon
  39. FDA. FDA approves first oral GLP-1 treatment for type 2 diabetes. 20 September 2019. prnewswire.com/news-releases/fda-approves-first-oral-glp-1-treatment-for-type-2-diabetes-300922431.html
  40. FDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 26 July 2024. fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  41. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 2019 (albumin binding; oral tablet with SNAC). pmc.ncbi.nlm.nih.gov/articles/PMC6474072
  42. Novo Nordisk. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults (once daily). 22 December 2025. novonordisk-us.com/media/press-releases/wegovy-pill-fda-approval-obesity.html
  43. Schultz S, Smith DR, Mock JJ, Schultz DA. Single-target molecule detection with nonbleaching multicolor optical immunolabels. PNAS, 2000, 97(3):996. doi.org/10.1073/pnas.97.3.996
  44. Tai LC et al. Methylxanthine drug monitoring with wearable sweat sensors. Advanced Materials, 2018, 30(23):e1707442. doi.org/10.1002/adma.201707442
  45. Mogera U et al. Wearable plasmonic paper-based microfluidics for continuous sweat analysis. Science Advances, 2022, 8(12):eabn1736 (speaker notes). doi.org/10.1126/sciadv.abn1736
  46. Ye C et al. A wearable aptamer nanobiosensor for non-invasive female hormone monitoring. Nature Nanotechnology, 2024, 19:330. doi.org/10.1038/s41565-023-01513-0
  47. UC San Diego, Qualcomm Institute. Sweat-powered sticker turns your drinking cup into a health sensor. 25 February 2026 (Biosensors and Bioelectronics). qi.ucsd.edu/sweat-powered-sticker-turns-your-drinking-cup-into-a-health-sensor
  48. Dexcom. Fourth quarter and fiscal year 2025 financial results. 12 February 2026. investors.dexcom.com/news/news-details/2026
  49. Dexcom. Fourth quarter and full year 2015 financial results. 23 February 2016. investors.dexcom.com/news/news-details/2016
  50. Mondal R, Saikia MJ. Advances in wearable biosensors for non-invasive biofluid monitoring. Biosensors, 2026, 16(6):336. doi.org/10.3390/bios16060336
  51. Apple. Apple debuts Apple Watch Series 11, featuring groundbreaking health insights (hypertension notifications). 9 September 2025. apple.com/newsroom/2025/09/apple-debuts-apple-watch-series-11-featuring-groundbreaking-health-insights
  52. MobiHealthNews. Apple receives FDA nod for hypertension notification feature. 15 September 2025. mobihealthnews.com/news/apple-receives-fda-nod-hypertension-notification-feature
  53. Goldsack JC et al. Verification, analytical validation, and clinical validation (V3). npj Digital Medicine, 2020, 3:55 (speaker notes). doi.org/10.1038/s41746-020-0260-4
  54. Frier Levitt. FDA peptides do-not-compound list update. 16 April 2026. frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026
  55. FDA. Evaluation memorandum on CJC-1295, presented to the Pharmacy Compounding Advisory Committee, 4 December 2024. fda.gov/media/183819/download
  56. PharmExec, 24 July 2026 (committee votes). pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
  57. BMJ, 28 July 2026 (six of seven). bmj.com/content/394/bmj-2026-100422
  58. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, FR Doc. 2026-22192, 30 October 2026 (the rulemaking quote and the revisit condition). public-inspection.federalregister.gov/2026-22192.pdf
  59. Holland & Knight. HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides. 4 November 2026 (the 10 conditions and lot-specific characterization data). hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding
  60. FDA, Pharmacy Compounding Advisory Committee briefing documents, July 2026. Criteria · BPC-157 (historical use: “insufficient information available to determine how long BPC-157-related BDSs have been used specifically in pharmacy compounding”) · KPV · TB-500
  61. Vasireddi et al. HSS Journal, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12313605
  62. Buchanan Ingersoll & Rooney. FDA Advisory Committee Voted Yes on Six Peptides. Now What? 18 August 2026 (the quote, organized information, stability, comments on a proposed rule). bipc.com/fda-voted-yes-on-six-peptides-now-what-the-regulatory-road-ahead
  63. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Updated 14 May 2026 (nominations, certificate of analysis). fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  64. FDA. Pharmacy Compounding Advisory Committee, notice of meeting, docket FDA-2025-N-6895. Federal Register, FR Doc. 2026-07361, 16 April 2026 (uses reviewed, docket deadline, nominator presentations; 2,643 comments as of 13 November 2026). federalregister.gov/documents/2026/04/16/2026-07361
  65. 21 CFR 216.23(c), the four criteria for the 503A Bulks List. law.cornell.edu/cfr/text/21/216.23
  66. US Pharmacist (ASHP). Detailing Sterile Compounding USP Chapter Changes. 29 December 2022 (USP <797>, up to 28 days after a multiple-dose container is first entered or punctured). uspharmacist.com/article/detailing-sterile-compounding-usp-chapter-changes
  67. Talay L, Hom J, Tan M, Ahuja N. Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany. Diabetes, Obesity and Metabolism, 2026 (546 of 4,535, 12%, adherent to medication and data submission at 12 months). doi.org/10.1111/dom.70916
  68. Chetty AK, Chen AS, Ross JS, Ramachandran R. Online Prescribing of GLP-1 Receptor Agonists. JAMA, 2026 (49 online sellers; 13 required a video visit). As reported by AJMC. doi.org/10.1001/jama.2026.9131
  69. Medscape. FDA expert panel backs compounding of six peptides, and the committee will meet before the end of February 2027 on LL-37, GHK-Cu, Dihexa acetate, PEG-MGF and Melanotan II. 28 July 2026. medscape.com
  70. Stone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, 7 September 2026. npr.org
  71. WHOTAG, GLOWCAST. Copper peptides climb ingredient rank 94 to 26 in 10 months, Instagram, 17 July 2026. whotag.ai
  72. Reddit, r/SkincareAddiction and r/TheOrdinarySkincare, threads on fitting copper peptides beside retinoids, vitamin C and acids, 2024 to 2026. reddit.com
  73. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine, 2025. pubmed.ncbi.nlm.nih.gov/40353578
  74. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine, 2023. pubmed.ncbi.nlm.nih.gov/37366315
  75. Ketonix AB, Sweden. Breath ketone meters, FAQ. shop.ketonix.com/pages/faq
  76. Lumen. Lumen and keto: Lumen measures CO2 in the breath and does not measure ketones. help.lumen.me
  77. Kummer M. Biosense review, editor's note that Biosense went out of business in September 2024. michaelkummer.com/biosense-review
  78. FDA. FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder (Scenesse, afamelanotide), 8 October 2019. fda.gov
  79. FDA. FDA approves first treatment for weight management for people with certain rare genetic conditions (Imcivree, setmelanotide), 27 November 2020. fda.gov
  80. FDA. FDA issues warning letter to Melanocorp, Inc. for illegal sale of Melanotan II, 2007. fda.gov
  81. NeurologyLive. FDA approves apitegromab for spinal muscular atrophy (Isembyld, Scholar Rock), 11 September 2026. neurologylive.com
  82. TechCrunch. Oura files to go public, 3 September 2026, on Oura's S-1 filing: revenue, paid members and retention. techcrunch.com
  83. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. pubmed.ncbi.nlm.nih.gov/18061177
  84. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis, 2012. pubmed.ncbi.nlm.nih.gov/22962027
  85. He L, et al. Frontiers in Pharmacology, 2022, on how BPC-157 is absorbed and cleared in rats and beagle dogs. pmc.ncbi.nlm.nih.gov/articles/PMC9794587
  86. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax). International Journal of Molecular Sciences, 2021, 22(12):6179. mdpi.com/1422-0067/22/12/6179
  87. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 2019. pmc.ncbi.nlm.nih.gov/articles/PMC6474072
  88. Novo Nordisk. Ozempic prescribing information, half-life of about one week. novo-pi.com/ozempic.pdf
  89. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 2026, 18(5):625. mdpi.com/1999-4923/18/5/625
  90. Wolters Kluwer. Understanding USP <797> beyond-use dates. 28 February 2025. wolterskluwer.com/en/expert-insights/usp-forum-update-beyond-use-dates-buds
  91. Frier Levitt. Clinician's corner: can I compound this? 17 February 2025. frierlevitt.com/articles/clinicians-corner-can-i-compound-this
  92. Medical Daily. AMA opposes unapproved peptide compounding policy. 12 November 2026. medicaldaily.com/ama-opposes-unapproved-peptide-compounding-policy-481192
  93. Health Law Alliance. Nonresident pharmacy licensure for compounders. 15 August 2026. healthlawalliance.com/blog/nonresident-pharmacy-licensure-for-compounders
  94. FDA. FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated. fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics
  95. FDA. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
  96. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018, 19(7):1987. pmc.ncbi.nlm.nih.gov/articles/PMC6073405
  97. Naturium. What are copper peptides? 7 October 2026 (citing Mortazavi et al., BioImpacts, 2024). naturium.com/blogs/the-lab-journal/what-are-copper-peptides
  98. Pratap A et al. Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants. npj Digital Medicine, 2020. nature.com/articles/s41746-020-0224-8
  99. Wing RR, Jeffery RW. Benefits of recruiting participants with friends and increasing social support for weight loss and maintenance. Journal of Consulting and Clinical Psychology, 1999, 67(1):132. pubmed.ncbi.nlm.nih.gov/10028217
  100. Project Baseline Health Study. Return of individual research results: what do participants prefer and expect? PLOS ONE, 2021. journals.plos.org/plosone/article?id=10.1371/journal.pone.0254153
  101. Tsaltskan V, Baez K, Firestein GS. Cost-effectiveness of social media advertising as a recruitment tool: a systematic review and meta-analysis. Journal of Clinical and Translational Science, 2023. cambridge.org/core/journals/journal-of-clinical-and-translational-science
  102. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nature Medicine, 2024. nature.com/articles/s41591-024-03018-2
  103. Abbott. Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes. 25 August 2026. abbott.mediaroom.com/2026-08-25
  104. KFF Health News. Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight. 1 June 2026. kffhealthnews.org/health-industry/glp1-weight-loss-drugs-telehealth-oversight-regulation-compounded-semaglutide
  105. KFF. Health Tracking Poll on GLP-1 use, fielded 27 October to 2 November 2025 among 1,350 adults. 14 November 2025. kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug
  106. Hims & Hers. Expanding Safe Access to Peptides, by Andrew Dudum. 29 October 2026. news.hims.com/newsroom/expanding-safe-access-to-peptides